InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Highly Accomplished Finance Professional as CFO
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced its appointment of Cindy Anderson as chief financial officer (“CFO”), effective Aug. 21, 2023. Anderson succeeds Jerrold Dotson, whose planned retirement was announced in July of this year. “We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team,” said Vistagen CEO Shawn Singh. “As CFO, Ms. Anderson will leverage deep experience in corporate strategic and financial operations while managing finance and growth objectives as we work to bring novel CNS treatments to patients. On behalf of Vistagen, I’d like to express our sincere gratitude to Mr. Dotson for his dedicated service and invaluable contributions to the company during his remarkable tenure. As he embarks on his retirement, we extend our best wishes for success and fulfillment in the future. At the same time, we remain steadfast in our work to advance our mission and enthusiastically welcome Ms. Anderson to our accomplished team.”
To view the full press release, visit https://ibn.fm/7LlDo
About VistaGen Therapeutics Inc.
Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol (“PH94B”), itruvone (“PH10”), “PH15,” “PH80,” and “PH284,” each an investigational agent belonging to a new class of drugs known as pherines, as well as “AV-101,” which is an oral prodrug of an antagonist of the N-methyl-D-aspartate receptor (“NMDAR”). Pherines are neuroactive nasal sprays designed with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information, visit the company’s website at www.Vistagen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork